Neoadjuvant trials in ER+ breast cancer: A tool for acceleration of drug development and discovery

Angel L. Guerrero-Zotano, Carlos L. Arteaga

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER+) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype. We review below the clinical benefits of neoadjuvant endocrine therapy for ER+/HER2-negative breast cancer, its use and limitations for drug development, prioritization of adjuvant and metastatic trials, and biomarker discovery. Significance: Neoadjuvant endocrine therapy is an excellent platform for the development of investigational drugs, triaging of novel combinations, biomarker validation, and discovery of mechanisms of drug resistance. This review summarizes the clinical and investigational benefits of this approach, with a focus on how to best integrate predictive biomarkers into novel clinical trial designs.

Original languageEnglish (US)
Pages (from-to)561-574
Number of pages14
JournalCancer Discovery
Volume7
Issue number6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Neoadjuvant Therapy
Drug Discovery
Biomarkers
Breast Neoplasms
Investigational Drugs
Drug Resistance
Estrogen Receptors
Clinical Trials
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Neoadjuvant trials in ER+ breast cancer : A tool for acceleration of drug development and discovery. / Guerrero-Zotano, Angel L.; Arteaga, Carlos L.

In: Cancer Discovery, Vol. 7, No. 6, 01.01.2017, p. 561-574.

Research output: Contribution to journalReview article

@article{e4bc1c69a71940b59ebfe97b914e3aac,
title = "Neoadjuvant trials in ER+ breast cancer: A tool for acceleration of drug development and discovery",
abstract = "Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER+) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype. We review below the clinical benefits of neoadjuvant endocrine therapy for ER+/HER2-negative breast cancer, its use and limitations for drug development, prioritization of adjuvant and metastatic trials, and biomarker discovery. Significance: Neoadjuvant endocrine therapy is an excellent platform for the development of investigational drugs, triaging of novel combinations, biomarker validation, and discovery of mechanisms of drug resistance. This review summarizes the clinical and investigational benefits of this approach, with a focus on how to best integrate predictive biomarkers into novel clinical trial designs.",
author = "Guerrero-Zotano, {Angel L.} and Arteaga, {Carlos L.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1158/2159-8290.CD-17-0228",
language = "English (US)",
volume = "7",
pages = "561--574",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Neoadjuvant trials in ER+ breast cancer

T2 - A tool for acceleration of drug development and discovery

AU - Guerrero-Zotano, Angel L.

AU - Arteaga, Carlos L.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER+) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype. We review below the clinical benefits of neoadjuvant endocrine therapy for ER+/HER2-negative breast cancer, its use and limitations for drug development, prioritization of adjuvant and metastatic trials, and biomarker discovery. Significance: Neoadjuvant endocrine therapy is an excellent platform for the development of investigational drugs, triaging of novel combinations, biomarker validation, and discovery of mechanisms of drug resistance. This review summarizes the clinical and investigational benefits of this approach, with a focus on how to best integrate predictive biomarkers into novel clinical trial designs.

AB - Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER+) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype. We review below the clinical benefits of neoadjuvant endocrine therapy for ER+/HER2-negative breast cancer, its use and limitations for drug development, prioritization of adjuvant and metastatic trials, and biomarker discovery. Significance: Neoadjuvant endocrine therapy is an excellent platform for the development of investigational drugs, triaging of novel combinations, biomarker validation, and discovery of mechanisms of drug resistance. This review summarizes the clinical and investigational benefits of this approach, with a focus on how to best integrate predictive biomarkers into novel clinical trial designs.

UR - http://www.scopus.com/inward/record.url?scp=85020408999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020408999&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-17-0228

DO - 10.1158/2159-8290.CD-17-0228

M3 - Review article

C2 - 28495849

AN - SCOPUS:85020408999

VL - 7

SP - 561

EP - 574

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 6

ER -